Pharmacokinetics of fluconazole in people with HIV infection: A population analysis

British Journal of Clinical Pharmacology

Volumn 41, Issue 4, 1996, Pages 291-298

  Mclachlan, A J ^a   Tett, S E ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

AIDS; Antifungal; Fluconazole; Population pharmacokinetics

Indexed keywords

FLUCONAZOLE;

ARTICLE; CELL COUNT; CREATININE CLEARANCE; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; POPULATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029986311     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03085.x     Document Type: Article

References (29)

1. Sugar AM. Treatment of fungal infections in patients infected with the human immunodeficiency virus. Pharmacother 1990; 10: 154s-158s.
2. Nelson MR Fisher M, Cartledge J, Rogers T, Gazzard BG. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994; 8: 651-654.
3. Milatovic D, Voss A. Efficacy of fluconazole in the treatment of systemic fungal infections. Eur J Clin Microbiol Infect Dis 1992; 11: 395-402.
4. Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with HIV infection compared with a group of males without HIV infection. Antimicrob Agents Chemother 1995; 39: 1835-1841.
5. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl): s318-s326.
6. Humphery MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and man. Antimicrob Agents Chemother 1985; 28: 648-653
7. DeMuria D, Forrest A, Rich J, Scavone JM, Cohen LG, Kazanjian PH. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2187-2192.
8. Yeates RA, Ruhnke M, Pfaff G, Hartmann A, Trautmann M, Sarnow E. The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients. Br J Clin Pharmacol 1994; 38: 77-79.
9. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: Theory and clinical application. Clin Pharmacokinet 1985; 11: 387-401.
10. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991; 32: 669-670.
11. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
12. Debruyne D, Ryckelynck J-P, Bigot M-C, Moulin M. Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector. J Pharm Sci 1988; 77: 534-535.
13. Gomeni R, Pineau G, Mentre F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res 1994; 14: 2321-2326.
14. Beal SL, Sheiner LB. NON MEM users guide. San Francisco, University of California.
15. Tett SE, Cutler DJ. Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur J Clin Pharmacol 1987; 31: 729-731.
16. Chin T, Fong IW, Vandenbroucke A. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis. Pharmacother 1990; 10: 305-307.
17. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
18. Fischman AJ, Alpert NM, Livni E, et al. Pharmacokinetics of 18F-labelled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 37: 1270-1277, 1993.
19. Debruyne D, Ryckelynck J-P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24: 10-27.
20. Kaniwa N, Aoyagi N, Ogata H, Ishi M. Application of the NONMEM method to evaluation of the bioavailability of drug products. J Pharm Sci 1990; 79: 1116-1120.
21. Unadkat JD, Agosti JM. Problems in pharmacokinetic investigations in patients with HIV infection. Clin Pharmacokinet 1990; 19: 172-176.
22. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990; 29: 221-226.
23. Forsmark CE. AIDS and the gastrointestinal tract. Postgrad Med 1993; 93: 143-148.
24. Bourne DWA. Mathematical Modeling of Pharmacokinetic Data, Pennsylvania: Technomic Publishing, 1995: 123-126.
25. Bourgoignie JJ. Renal complications of human immunodeficiency virus type 1. Kidney Int 1990; 37: 1571-1584.
26. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother 1993; 37: 1137-1143.
27. Macnab KA, Gill MJ, Sutherland LR, De Boer Visser N, Church D. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993; 31: 421-428.
28. Revell P, O'Doherty MJ, Tang A, Savidge GF. Folic acid absorption in patients infected with human immunodeficiency virus. J Int Med 1991; 230: 227-231.
29. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529-535.